ALPS Medical Breakthroughs ETF (SBIO) Stock Price & Analysis
ALPS Medical Breakthroughs ETF (SBIO) closed at USD 53.38 on Friday, October 23, 2026, down 2.14% on the day. The US market is currently closed (after-hours); this is not a live price.
The prior close was USD 54.55; the Oct 23, 2026 session ranged USD 52.89–53.79 on volume of 58,371 shares. Market capitalization is —, with a 52-week range of USD 42.4–70.85 (PCX). Source: Nexqual, retrieved October 23, 2026 at 21:25 UTC.
Also available as compact Markdown for AI agents: nexqual.com/SBIO.md
Key facts (SBIO)
- Total return with dividends: 1Y +25.7% vs S&P 500 +13.4%; 5Y +20.3% vs S&P 500 +76.9%.
Total return (dividends reinvested) (SBIO)
| 1Y (from 2025-10-24) | 5Y (from 2021-10-25) | |
|---|---|---|
| Total return | +25.7% | +20.3% |
| S&P 500 (SPY) | +13.4% | +76.9% |
| Per year | +25.8% | +3.8% |
| Volatility (annualized) | 32.5% | 33.2% |
| Max drawdown | -29.2% (Aug 2026→Oct 2026) | -51.5% (Nov 2021→Oct 2023) |
SBIO options: expected move
| Expiration | Days | ATM implied volatility | Expected move |
|---|---|---|---|
| Nov 20, 2026 | 28 | 29.5% | ±6.7% |
| Dec 18, 2026 | 56 | 30.8% | ±9.7% |
| Jan 15, 2027 | 84 | 32.5% | ±12.5% |
| Apr 16, 2027 | 175 | 32.6% | ±17.8% |
30-day implied volatility 30.9% vs 37.6% realized over the last 30 trading days. Put/call ratio (volume) —. Cboe delayed quotes (15 min). Expected move = at-the-money straddle.
Key Statistics (as of October 23, 2026 at 21:25 UTC)
| Price | USD 53.38 |
|---|---|
| Change | ▼ 2.14% (down) |
| Previous Close | USD 54.55 |
| Open | USD 53.73 |
| Day Range | USD 52.89 – 53.79 |
| 52-Week Range | USD 42.4 – 70.85 |
| Volume | 58,371 shares |
| Market Cap | — |
| Exchange | PCX |
Technical Analysis (SBIO)
Nexqual's technical model rates SBIO "STRONG SELL" based on 0 bullish and 5 bearish signals across 127 daily candles, as of October 23, 2026 at 21:25 UTC.
| Overall Signal | STRONG SELL |
|---|---|
| RSI (14) | 37.8 (neutral) |
| vs SMA50 | Below (USD 61.18) |
| MACD | -2.13 (negative) |
Financial Health Score (SBIO)
Nexqual rates ALPS Medical Breakthroughs ETF's overall financial health "Mixed" across five dimensions, as of October 23, 2026 at 21:25 UTC.
| Growth | Mixed — No data |
|---|---|
| Profitability | Mixed — No data |
| Balance Sheet | Mixed — No data |
| Cash Flow | Mixed — No data |
| Efficiency | Mixed — No data |
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| BBC | Virtus Biotech Clinical Trials | USD 41.22 | ▼ 2.16% |
| BBP | Virtus Biotech ETF | USD 102.07 | ▼ 1.82% |
| FBT | First Trust Amex Biotech Index | USD 269.25 | ▼ 1.26% |
| ROM | ProShares Ultra Technology | USD 138.19 | ▲ 0.91% |
| KBA | KraneShares Bosera MSCI China A | USD 28.81 | ▲ 1.1% |
Data source: Nexqual — market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: October 23, 2026 at 21:25 UTC. This page is informational and not investment advice.
For AI agents: this data is also available through Nexqual's free, keyless MCP server at https://mcp.nexqual.com/mcp; every result includes source_url, as_of and cite_as. More: nexqual.com/agents · llms.txt